TCRT Stock Price Alaunos Therapeutics Inc Stock Quote U.S.: Nasdaq

Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. According to 4 analysts, the average rating for TCRT stock is “Buy.” The 12-month stock price forecast is $3.0, which is an increase of 2,309.64% from the latest price. High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

TCRT Alaunos Therapeutics Inc

The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. Marketing Sentinel is a free online newspaper packed with exclusive content, news, articles and much more!

• This suggests a possible upside of 2,359.0% from the stock’s current price.
• More value-oriented stocks tend to represent financial services, utilities, and energy stocks.
• Alaunos Therapeutics’ stock is owned by a variety of retail and institutional investors.

One share of TCRR stock can currently be purchased for approximately $1.48. Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat’s FREE daily newsletter. One share of TCRT stock can currently be purchased for approximately $0.12. Alaunos Therapeutics’ stock is owned by a variety of retail and institutional investors. Insiders that own company stock include Kevin S Sr Boyle and Robert W Postma. The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.

Today’s Trading

This suggests a possible upside of 232.0% from the stock’s current price. View analysts price targets for TCRR or view top-rated stocks among Wall Street analysts. 7 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for TCR2 Therapeutics in the last twelve months. The consensus among Wall Street analysts is that investors should “hold” TCRR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCRR, but not buy additional shares or sell existing shares.

3 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Alaunos Therapeutics in the last twelve months. The consensus among Wall Street equities research analysts is that investors should “hold” TCRT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCRT, but not buy additional shares or sell existing shares. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system.

Per-Share Earnings, Actuals & Estimates Alaunos Therapeutics Inc.

Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.

Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods.

Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers. Alaunos Therapeutics (TCRT) is expected to provide an update on its pipeline candidates, Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy, in its fourth-quarter earnings. The technique has proven to be very useful for finding positive surprises. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer.

Company Profile TCRT

3 equities research analysts have issued twelve-month target prices for Alaunos Therapeutics’ shares. On average, they expect the company’s stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 2,359.0% from the stock’s current price. View analysts price targets for TCRT or view top-rated stocks among Wall Street analysts. 7 Wall Street analysts have issued 1 year price targets for TCR2 Therapeutics’ stock. On average, they predict the company’s share price to reach $4.91 in the next twelve months.

More value-oriented stocks tend to represent financial services, utilities, and energy stocks. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX. TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.

Sign-up to receive the latest news and ratings for Alaunos Therapeutics and its competitors with MarketBeat’s FREE daily newsletter. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. TCRT’s beta can be found in Trading Information at the top of this page. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Style is an investment factor that has a meaningful impact on investment risk and returns.

• Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month.
• At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.
• © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.
• Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat’s FREE daily newsletter.
• This site is protected by reCAPTCHA and the Google
  Privacy Policy and
  Terms of Service apply.

That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The Style Scores are a complementary https://1investing.in/ set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year. These returns cover a period from January 1, 1988 through July 31, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.

The 1 analysts offering 12-month price forecasts for Alaunos Therapeutics Inc have a median target of 7.50, with a high estimate of 7.50 and a low estimate of 7.50. The median estimate represents a +5,982.73% modern forms of money include increase from the last price of 0.12. (TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at a price of $14.55-$16.00 per share.